UCLA researchers create non-invasive clear-cell kidney cancer imaging technique with 85.5% sensitivity and 87% specificity.

Researchers at UCLA's Jonsson Comprehensive Cancer Center have developed a non-invasive imaging technique that accurately detects clear-cell renal cell carcinoma, the most common kidney cancer. Utilizing the antibody drug 89Zr-TLX250, which targets the CA9 protein, the method shows 85.5% sensitivity and 87% specificity. This advancement could reduce unnecessary surgeries and improve treatment accuracy, potentially transforming kidney cancer diagnostics and management.

October 03, 2024
9 Articles